PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in oncology Ročník 12; s. 819128
Hlavní autoři: Peng, Yan, Wang, Yuanyuan, Zhou, Cheng, Mei, Wuxuan, Zeng, Changchun
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 24.03.2022
Témata:
cancer
oncogenic alterations
Oncology
PI3K/Akt/mTOR pathway
precision medicine
targeted therapy
oncogenic alterations
targeted therapy
precision medicine
cancer
PI3K/Akt/mTOR pathway
ISSN:2234-943X, 2234-943X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Enrique Gonzalez Billalabeitia, Hospital Universitario 12 de Octubre, Spain; Xiaoyong Fu, Baylor College of Medicine, United States
Edited by: Yan-yan Yan, Shanxi Datong University, China
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.819128